As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Werber covers the Healthcare sector, focusing on stocks such as Amgen, BioNTech SE, and Ultragenyx Pharmaceutical ... development and commercialization of novel products for the treatment of serious ...

The South African Health Products Regulatory Authority (Sahpra ... a class of medications that can help manage diabetes and ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price ...

When it comes to pharma and biotech giants ... Therapeutics after the companies signed a consent order whose terms included ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

As it becomes clearer that Indian markets have to deal with domestic slowdown and increased uncertainty under Donald Trump’s ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...